Literature DB >> 27789931

Evolocumab.

.   

Abstract

Entities:  

Year:  2016        PMID： 27789931      PMCID： PMC5079792          DOI： 10.18773/austprescr.2016.078

Source DB:  PubMed          Journal:  Aust Prescr        ISSN： 0312-8008


× No keyword cloud information.
  10 in total

Review 1.  PCSK9 inhibitors - mechanisms of action.

Authors:  Michael M Page; Gerald F Watts
Journal:  Aust Prescr       Date:  2016-10-01

Review 2.  PCSK9 inhibitors - clinical applications.

Authors:  Robert Schmidli
Journal:  Aust Prescr       Date:  2016-10-01

3.  A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.

Authors:  Dirk J Blom; Tomas Hala; Michael Bolognese; Michael J Lillestol; Phillip D Toth; Lesley Burgess; Richard Ceska; Eli Roth; Michael J Koren; Christie M Ballantyne; Maria Laura Monsalvo; Kate Tsirtsonis; Jae B Kim; Rob Scott; Scott M Wasserman; Evan A Stein
Journal:  N Engl J Med       Date:  2014-03-29       Impact factor: 91.245

4.  Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

Authors:  Marc S Sabatine; Robert P Giugliano; Stephen D Wiviott; Frederick J Raal; Dirk J Blom; Jennifer Robinson; Christie M Ballantyne; Ransi Somaratne; Jason Legg; Scott M Wasserman; Robert Scott; Michael J Koren; Evan A Stein
Journal:  N Engl J Med       Date:  2015-03-15       Impact factor: 91.245

Review 5.  Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis.

Authors:  Eliano Pio Navarese; Michalina Kolodziejczak; Volker Schulze; Paul A Gurbel; Udaya Tantry; Yingfeng Lin; Maximilian Brockmeyer; David E Kandzari; Julia M Kubica; Ralph B D'Agostino; Jacek Kubica; Massimo Volpe; Stefan Agewall; Dean J Kereiakes; Malte Kelm
Journal:  Ann Intern Med       Date:  2015-07-07       Impact factor: 25.391

6.  Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial.

Authors:  Frederick J Raal; Narimon Honarpour; Dirk J Blom; G Kees Hovingh; Feng Xu; Rob Scott; Scott M Wasserman; Evan A Stein
Journal:  Lancet       Date:  2014-10-01       Impact factor: 79.321

7.  PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.

Authors:  Frederick J Raal; Evan A Stein; Robert Dufour; Traci Turner; Fernando Civeira; Lesley Burgess; Gisle Langslet; Russell Scott; Anders G Olsson; David Sullivan; G Kees Hovingh; Bertrand Cariou; Ioanna Gouni-Berthold; Ransi Somaratne; Ian Bridges; Rob Scott; Scott M Wasserman; Daniel Gaudet
Journal:  Lancet       Date:  2014-10-01       Impact factor: 79.321

8.  Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.

Authors:  Jennifer G Robinson; Bettina S Nedergaard; William J Rogers; Jonathan Fialkow; Joel M Neutel; David Ramstad; Ransi Somaratne; Jason C Legg; Patric Nelson; Rob Scott; Scott M Wasserman; Robert Weiss
Journal:  JAMA       Date:  2014-05-14       Impact factor: 56.272

9.  Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.

Authors:  Erik Stroes; David Colquhoun; David Sullivan; Fernando Civeira; Robert S Rosenson; Gerald F Watts; Eric Bruckert; Leslie Cho; Ricardo Dent; Beat Knusel; Allen Xue; Rob Scott; Scott M Wasserman; Michael Rocco
Journal:  J Am Coll Cardiol       Date:  2014-03-30       Impact factor: 24.094

10.  Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab.

Authors:  Michael J Koren; Pernille Lundqvist; Michael Bolognese; Joel M Neutel; Maria Laura Monsalvo; Jingyuan Yang; Jae B Kim; Rob Scott; Scott M Wasserman; Harold Bays
Journal:  J Am Coll Cardiol       Date:  2014-03-29       Impact factor: 24.094
  10 in total
  1 in total

Review 1.  PCSK9 inhibitors - clinical applications.

Authors:  Robert Schmidli
Journal:  Aust Prescr       Date:  2016-10-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.